Antiviral drug remdesivir has been approved by US regulators to treat hospitalised Covid-19 patients.
After studies showed remdesivir a drug previously used to treat ebola patients, shortened recovery time by 31 percent, or around four days on average, for hospitalised Covid-19 patients, Food and Drug Administration (FDA) cleared its use.
Patients given the remdesivir drug were able to leave the hospital in 11 days on average, compared to 15 days for the placebo group. The drug may also help avert deaths, but that effect is not yet large enough for scientists to know for sure.
Coronavirus: US Approves Use Of Remdesivir To Treat Coronavirus Patients
READ ALSO: HIV Drug Leronlimab Successfully Treats Coronavirus, On 2nd Trial
Now, the drug can be administered to patients with severe conditions, such as those experiencing breathing problems requiring supplemental oxygen or ventilators.
In normal times the FDA requires “substantial evidence” of a drug’s safety and effectiveness, usually through one or more large, rigorously controlled patient studies.
But during public health emergencies the agency can waive those standards and require only that an experimental treatment’s potential benefits outweigh its risks.
Follow us on, Facebook
Post Disclaimer
The opinions, beliefs and viewpoints expressed by the author and forum participants on this website do not necessarily reflect the opinions, beliefs and viewpoints of Anaedo Online or official policies of the Anaedo Online.